HomeCompareTYME vs MO

TYME vs MO: Dividend Comparison 2026

TYME yields 643.71% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TYME wins by $456723.61M in total portfolio value
10 years
TYME
TYME
● Live price
643.71%
Share price
$0.31
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$456723.69M
Annual income
$349,819,815,541.55
Full TYME calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — TYME vs MO

📍 TYME pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTYMEMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TYME + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TYME pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TYME
Annual income on $10K today (after 15% tax)
$54,715.16/yr
After 10yr DRIP, annual income (after tax)
$297,346,843,210.32/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, TYME beats the other by $297,346,817,575.02/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TYME + MO for your $10,000?

TYME: 50%MO: 50%
100% MO50/50100% TYME
Portfolio after 10yr
$228361.88M
Annual income
$174,909,922,850.36/yr
Blended yield
76.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

TYME
No analyst data
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TYME buys
0
MO buys
0
No recent congressional trades found for TYME or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTYMEMO
Forward yield643.71%6.36%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$456723.69M$80.1K
Annual income after 10y$349,819,815,541.55$30,159.17
Total dividends collected$447927.36M$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: TYME vs MO ($10,000, DRIP)

YearTYME PortfolioTYME Income/yrMO PortfolioMO Income/yrGap
1← crossover$75,071$64,370.78$10,570$780.30+$64.5KTYME
2$531,949$451,622.81$11,381$1,032.90+$520.6KTYME
3$3,560,009$2,990,823.66$12,535$1,392.73+$3.55MTYME
4$22,515,533$18,706,324.17$14,193$1,920.91+$22.50MTYME
5$134,661,254$110,569,633.76$16,618$2,723.68+$134.64MTYME
6$762,121,745$618,034,202.42$20,263$3,993.80+$762.10MTYME
7$4,084,436,460$3,268,966,193.63$25,936$6,098.36+$4084.41MTYME
8$20,743,580,045$16,373,233,031.81$35,166$9,775.01+$20743.54MTYME
9$99,910,162,010$77,714,531,362.55$51,026$16,597.78+$99910.11MTYME
10$456,723,688,892$349,819,815,541.55$80,113$30,159.17+$456723.61MTYME

TYME vs MO: Complete Analysis 2026

TYMEStock

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. As of September 16, 2022, Tyme Technologies, Inc. operates as a subsidiary of Syros Pharmaceuticals, Inc.

Full TYME Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this TYME vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TYME vs SCHDTYME vs JEPITYME vs OTYME vs KOTYME vs MAINTYME vs PMTYME vs BTITYME vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.